StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) stock

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.17−0.04 (-0.12%)

Close on Nov 18, 2026Market cap $6.85BP/E –Yield –

Immunovant revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

No revenue figures for Immunovant

Immunovant has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Immunovant figures

See a number that looks wrong?